Advanced Circulatory Adds Fernando Yuste, MBA Ph.D. as Critical Care Business Unit Manager
Minneapolis, MN - Advanced Circulatory, makers of multiple medical devices and the pioneer of Perfusion on DemandTM therapy, has named Fernando Yuste, MBA Ph.D. as Manager of the company’s newly established Critical Care Business Unit. In this role, Yuste will supervise the expansion of Advanced Circulatory’s product lines into the acute and critical care market.
Dr. Yuste joins Advanced Circulatory from Medivance/CR Bard, and he has over 15 years of international experience in the medical device industry with positions ranging from management, sales and marketing, product development, clinical affairs, and business development. He has worked with several successful start-ups, including the German company GMS GmbH, manufacturer of the Licox brain oxygen monitor, acquired by Integra LifeSciences in 2001, and the temperature management company Medivance, acquired by CR Bard in 2011. He has also held positions with Integra NeuroSciences and Terumo Interventional Systems. In his native country of Spain, Dr. Yuste worked in sales and marketing in a distributor company that sold neurologic products for Medtronic, Elekta, and Integra, among others. Dr. Yuste holds a Ph.D. degree in Physics from the University of Madrid and an MBA, Marketing Specialty, from ESADE Business School. Before starting his career in the medical device industry he spent several years working in a hospital in the Medical Physics Department.
“Fernando brings a deep and broad foundation of knowledge and experience in the critical care market, and we are fortunate to have him as a member of the team,” commented Mike Black, Advanced Circulatory’s CEO.
About Advanced Circulatory
Advanced Circulatory is the pioneer of a novel technology platform called Perfusion on Demand™ - a therapy with far-reaching implications for multiple medical conditions. This non-invasive therapy increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised, giving rescuers, clinicians and caregivers the potential to return patients to a full life after severe medical emergencies. The company manufactures and markets the ResQPOD® (Perfusion on Demand) and the ResQGARD™ Impedance Threshold Devices, which are sold in over 25 countries worldwide.